Journal of Thoracic Oncology · 2023 · 98 citations · 22 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyCancer ImmunotherapyCombination ChemotherapyCytotoxic ChemotherapyLung Cancer PharmacotherapyFollow-up DurationPlacebo-controlled Efficacy AssessmentProgrammed Cell Death Protein 1 InhibitorsProgrammed Cell Death Protein 1 RegulationProgrammed Death-ligand 1 InhibitionProgrammed Death-ligand 1 InhibitorsProgrammed Death-ligand 1 SignalingProgrammed Death-ligand 1 Targeting
22
The National Comprehensive Cancer Network
William T. McGivney · Cancer · 1998 · 16.9K citations
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel et al. · New England Journal of Medicine · 2018 · 6.6K citations · Full text
Medicine, Oncology, Pharmacology +16
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo et al. · New England Journal of Medicine · 2018 · 3.8K citations · Full text
Medicine, Oncology, Pharmacology +16
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
Luis Paz‐Ares, Alexander Luft, David Vicente et al. · New England Journal of Medicine · 2018 · 3.6K citations · Full text
Medicine, Oncology, Pharmacotherapy +17